BRPI0406749A - Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica - Google Patents

Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica

Info

Publication number
BRPI0406749A
BRPI0406749A BR0406749-5A BRPI0406749A BRPI0406749A BR PI0406749 A BRPI0406749 A BR PI0406749A BR PI0406749 A BRPI0406749 A BR PI0406749A BR PI0406749 A BRPI0406749 A BR PI0406749A
Authority
BR
Brazil
Prior art keywords
functional
treatment
present
patient
nari
Prior art date
Application number
BR0406749-5A
Other languages
English (en)
Inventor
Steven B Landau
Original Assignee
Dynogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals Inc filed Critical Dynogen Pharmaceuticals Inc
Publication of BRPI0406749A publication Critical patent/BRPI0406749A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"MéTODOS RELACIONADOS AO TRATAMENTO DE DISTúRBIOS FUNCIONAIS DO INTESTINO E COMPOSIçãO FARMACêUTICA". A presente invenção refere-se a um método de tratamento de um distúrbio funcional de intestino em um paciente em necessidade do tratamento. O método compreende administrar ao paciente em necessidade do tratamento, uma quantidade terapeuticamente eficaz de um composto que é dotado de atividade de antagonista receptor 5-HT~ 3~ e de atividade inibidora de reabsorção de noradrenalina (NARI). A presente invenção se refere, adicionalmente, a um método de tratamento de um distúrbio funcional de intestino em um paciente que necessite do mesmo, compreendendo co-administrar ao referido paciente, uma primeira quantidade de um antagonista receptor 5-HT~ 3~ e uma segunda quantidade de um NARI, onde as primeira e segunda quantidades compreendem, juntas, uma quantidade terapeuticamente eficaz ou cada uma delas está presente em uma quantidade terapeuticamente eficaz. Ademais, o método da presente invenção compreende a administração do NARI isoladamente. Os distúrbios funcionais do intestino que podem ser tratados de acordo com o método da presente invenção incluem IBS, dilatação abdominal funcional, constipação funcional e diarréia funcional.
BR0406749-5A 2003-01-13 2004-01-13 Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica BRPI0406749A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44007703P 2003-01-13 2003-01-13
US49248003P 2003-08-04 2003-08-04
PCT/US2004/000807 WO2004062623A2 (en) 2003-01-13 2004-01-13 Method of treating functional bowel disorders

Publications (1)

Publication Number Publication Date
BRPI0406749A true BRPI0406749A (pt) 2005-12-20

Family

ID=32718145

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406749-5A BRPI0406749A (pt) 2003-01-13 2004-01-13 Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica

Country Status (13)

Country Link
US (8) US20040147509A1 (pt)
EP (2) EP2286817A3 (pt)
JP (2) JP2006516976A (pt)
KR (1) KR20050111318A (pt)
CN (1) CN100353946C (pt)
AU (1) AU2004204825B2 (pt)
BR (1) BRPI0406749A (pt)
CA (1) CA2512983A1 (pt)
MX (1) MXPA05007381A (pt)
NZ (1) NZ541008A (pt)
PL (1) PL378367A1 (pt)
WO (1) WO2004062623A2 (pt)
ZA (1) ZA200505817B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
JP2006516977A (ja) * 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
NZ541008A (en) * 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating functional bowel disorders
DE602004007225T2 (de) * 2003-04-04 2008-03-06 Dynogen Pharmaceuticals Inc., Waltham Methode zur behandlung von erkrankungen der unteren harnwege
EP1857816B1 (en) * 2005-01-28 2010-03-10 Astellas Pharma Inc. Method of screening therapeutic agent for irritable bowel syndrome
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
EP1906951A4 (en) * 2005-07-01 2009-05-27 Dynogen Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING HYPOMOTILITY OF THE DIGESTIVE SYSTEM AND RELATED DISORDERS
WO2007041772A1 (en) * 2005-10-07 2007-04-19 Colocaps Pty Ltd Preparation for the treatment of diarrhoea
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
EP2120122B1 (en) * 2005-12-02 2013-10-30 iRobot Corporation Coverage robot mobility
WO2007120445A1 (en) * 2006-03-31 2007-10-25 Dynogen Pharmaceuticals, Inc. SOLUBLE SALTS OF THIENO [2,3-d] PYRIMIDINE DERIVATIVES
TW200838534A (en) * 2007-02-07 2008-10-01 Astellas Pharma Inc Treatment for irritable bowel syndrome
US20110158930A1 (en) * 2008-08-28 2011-06-30 Astellas Pharma Inc. Method for treatment of irritable bowel syndrome
DK2744497T3 (en) * 2011-10-18 2016-08-01 Helsinn Healthcare Sa THERAPEUTIC COMBINATION OF netupitant AND palonosetron
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
ES2955693T3 (es) 2012-12-24 2023-12-05 Neurogastrx Inc Métodos para el tratamiento de trastornos del tracto GI
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
PL3201203T3 (pl) * 2014-09-29 2021-11-22 Takeda Pharmaceutical Company Limited Krystaliczna postać 1-(1-metylo-1h-pirazol-4-ilo)-n-((1r,5s,7s)-9-metylo-3-oksa-9-azabicyklo[3.3.1]nonan-7-ylo)-1h-indolo-3-karboksyamidu
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
WO2022104234A1 (en) * 2020-11-15 2022-05-19 Castor Trevor P Methods for assaying and measuring the efficacy of anti-nausea compounds
CN113412817B (zh) * 2021-05-31 2022-07-12 成都中医药大学附属医院 提高成模率减少死亡率的ibs-d实验动物模型方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US659336A (en) * 1900-05-25 1900-10-09 Charles H Booth Pipe-coupling.
JPS60146891A (ja) * 1984-01-05 1985-08-02 Mitsubishi Chem Ind Ltd 〔２，３−ｄ〕チエノピリミジン誘導体およびその塩
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
EP0297651B1 (en) * 1987-06-29 1993-11-03 Duphar International Research B.V Anellated indole derivatives
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5530008A (en) * 1989-04-21 1996-06-25 Sandoz Ltd. Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
EP1022025A3 (en) * 1991-06-26 2002-06-05 Sepracor, Inc. Method and compositions for treating emesis nausea and other disorders using optically pure R(+) ondansetron
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
US5262428A (en) * 1992-03-13 1993-11-16 Wake Forest University Biologically active tropane derivatives
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
WO1993018755A1 (en) 1992-03-25 1993-09-30 Depomed Systems, Incorporated Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
DE4238553A1 (de) * 1992-11-14 1994-05-19 Kali Chemie Pharma Gmbh Neue Imidazol-1-yl-Verbindungen enthaltende Arzneimittel
JPH0616557A (ja) * 1992-12-21 1994-01-25 Mitsubishi Kasei Corp 脳機能障害改善剤
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
MY113062A (en) * 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
CA2220451A1 (en) * 1995-05-17 1996-11-21 Cedars-Sinai Medical Center Methods and compositions for improving digestion and absorption in the small intestine
EP0855397B1 (en) * 1995-07-28 2001-05-09 Dainippon Pharmaceutical Co., Ltd. (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridine-carboxamide, process for producing the same and medicinal composition containing the same
AU702594B2 (en) * 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds
AU1767997A (en) * 1996-02-15 1997-09-02 Janssen Pharmaceutica N.V. Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
SE9701304D0 (sv) * 1997-04-09 1997-04-09 Astra Pharma Prod Compounds
ES2202855T3 (es) * 1997-04-18 2004-04-01 Janssen Pharmaceutica Nv Uso de antagonistas 5ht3 para promover el lavado intestinal.
US6177879B1 (en) * 1997-05-09 2001-01-23 Honda Giken Kogyo Kabushiki Kaisha Battery rental system and apparatus
JP4083818B2 (ja) 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
DE19813661A1 (de) * 1997-08-01 1999-02-04 Solvay Pharm Gmbh Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron
DE19734444A1 (de) * 1997-08-08 1999-02-11 Basf Ag 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
US6117879A (en) * 1997-09-16 2000-09-12 Solvay Pharmaceuticals Gmbh Methods of using moxonidine to inhibit nociceptive pain
DK0901790T3 (da) * 1997-09-16 2001-08-06 Solvay Pharm Gmbh Anvendelse af moxonidin til behandling af neuropatisk smerte
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US6211171B1 (en) * 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
US6456458B1 (en) * 1998-08-08 2002-09-24 Nidec Corporation Disk-drive motor rotating on a magnetically counterbalanced single hydrodynamic thrust bearing
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
WO2000048581A2 (en) * 1999-02-18 2000-08-24 Novartis Ag Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
WO2000048597A1 (en) * 1999-02-18 2000-08-24 Novartis Ag Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
DE19911371A1 (de) * 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
US6448962B1 (en) 1999-05-14 2002-09-10 Three-Five Systems, Inc. Safety timer to protect a display from fault conditions
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
PT1632234E (pt) * 1999-07-01 2007-07-09 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
EP1790334A3 (en) 1999-11-02 2008-02-20 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
IL150568A0 (en) 2000-02-04 2003-02-12 Depomed Inc A controlled release oral drug dosage form
JP2001243182A (ja) 2000-02-29 2001-09-07 Nec Corp サーバシステム及びＷｅｂコンテンツとサーバシステムとの連動方法
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6566369B2 (en) * 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US6588708B2 (en) * 2001-01-29 2003-07-08 The Boeing Company Spacecraft methods and structures for acquiring and determining power-safe attitudes
US20020107244A1 (en) * 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0112494D0 (en) * 2001-05-22 2001-07-11 Arachnova Therapeutics Ltd New therapeutic use
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
MXPA03011096A (es) 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
US6568519B2 (en) 2001-08-10 2003-05-27 Borgwarner, Inc. Torque limiting chain sprocket assembly
US6475078B1 (en) * 2001-10-09 2002-11-05 Norb Borcherding Air ventilating device
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US7413751B2 (en) 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6458795B1 (en) * 2001-11-15 2002-10-01 University Of Florida Method and composition for treatment of irritable bowel disease
CA2473392A1 (en) * 2002-01-18 2003-07-31 Aryx Therapeutics 5-ht3 receptor antagonists and methods of use
GB0202265D0 (en) * 2002-01-31 2002-03-20 Arachnova Therapeutics Ltd New therapeutic use
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
US20040032780A1 (en) * 2002-04-08 2004-02-19 Ehud Langberg System and method for generating a clock signal in a communication system
CA2491836C (en) * 2002-07-10 2011-01-25 Arachnova Therapeutics Ltd. 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder
JP2006500427A (ja) * 2002-08-29 2006-01-05 アラクノーバ・セラピューティックス・リミテッド （４−（２−フルオロフェニル）−６−メチル−２−（１−ピペラジニル）チエノ［２，３−ｄ］ピリミジンの新規治療的使用
JP2006516977A (ja) * 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
NZ541008A (en) * 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating functional bowel disorders

Also Published As

Publication number Publication date
WO2004062623A3 (en) 2005-06-09
CN100353946C (zh) 2007-12-12
EP2286817A2 (en) 2011-02-23
MXPA05007381A (es) 2006-02-10
AU2004204825A1 (en) 2004-07-29
EP2286817A3 (en) 2011-06-15
US20040254168A1 (en) 2004-12-16
US20040254169A1 (en) 2004-12-16
NZ541008A (en) 2007-09-28
EP1558081A2 (en) 2005-08-03
CA2512983A1 (en) 2004-07-29
JP2006516976A (ja) 2006-07-13
AU2004204825B2 (en) 2007-07-19
WO2004062623A2 (en) 2004-07-29
US20050032780A1 (en) 2005-02-10
KR20050111318A (ko) 2005-11-24
PL378367A1 (pl) 2006-04-03
ZA200505817B (en) 2006-04-26
US20040254170A1 (en) 2004-12-16
US20060217391A1 (en) 2006-09-28
EP1558081A4 (en) 2006-06-14
US20050192270A1 (en) 2005-09-01
US20040259862A1 (en) 2004-12-23
JP2011157372A (ja) 2011-08-18
CN1750759A (zh) 2006-03-22
US20040147509A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
BRPI0406749A (pt) Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica
Bassari et al. Jaundice associated pruritis: a review of pathophysiology and treatment
MA29326B1 (fr) Combinaison de composes organiques
DE602006021444D1 (de) Therapie zur behandlung der überaktiven blase
BRPI0410273A (pt) métodos de tratamento de aterosclerose e de aumento dos nìveis de hdl no soro em um paciente humano em necessidade de tal tratamento, e, composição farmacêutica
US20100063062A1 (en) Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts
BRPI0622054B8 (pt) composto e composição farmacêutica
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
DE602005018758D1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
Summey Jr et al. Pharmacologic advances in the systemic treatment of itch
ME02495B (me) Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
EA200400982A1 (ru) Способы лечения пациентов, страдающих от нарушения движений
EA200800007A1 (ru) Фармацевтические композиции на основе нейроактивного стероида и их применение
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
BRPI0517485A (pt) composto, composição farmacêutica, método de tratamento de doença em mamìferos, método de aumento da atividade de receptor colinérgico, método de tratamento, prevenção ou alìvio dos sintomas associados a disfunção em mamìfero e/ao aumento da pressão intraocular ou glaucoma
EA200970706A1 (ru) Новые фармацевтические композиции
Thase et al. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder
WO2010124283A4 (en) Methods and compositions relating to hematologic malignancies
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
Lauerma Successful treatment of citalopram‐induced anorgasmia by cyproheptadine
BRPI0411608A (pt) derivado de 8-aza-biciclo [3.2.1] octano, composição farmacêutica, uso do composto, e, método de tratamento, prevenção ou alìvio de uma doença, um distúrbio ou uma condição de um organismo animal vivo
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.